UMIN-CTR Clinical Trial

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000046893
Receipt No. R000053504
Scientific Title Clinical effects of extension of meal intake time in patients with type 2 diabetes: a prospective observational study
Date of disclosure of the study information 2022/02/13
Last modified on 2022/02/13 (Ver. 1)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Clinical effects of meal intake time intervention in patients with type 2 diabetes: a prospective observational study
Acronym Meal intake time intervention study
Scientific Title Clinical effects of extension of meal intake time in patients with type 2 diabetes: a prospective observational study
Scientific Title:Acronym Meal intake time intervention study
Region
Japan

Condition
Condition type 2 diabetes
Classification by specialty
Endocrinology and Metabolism
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 The aim of this study is to investigate the clinical effect of extension of meal intake time in patients with type 2 diabetes.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Explanatory
Developmental phase Not applicable

Assessment
Primary outcomes Comparing the difference in HbA1c between normal nutritional guidance and same nutritional guidance plus extension of meal intake time for dinner.
Key secondary outcomes 1: Comparing the difference in body weight and/or BMI between normal nutritional guidance and same nutritional guidance plus extension of meal intake time for dinner.
2: Comparing the difference in several factors as follow between normal nutritional guidance and same nutritional guidance plus extension of meal intake time for dinner.
1.GA
2.FPG (mg/dL)
3.systolic blood pressure (mmHg)
4.diastolic blood pressure (mmHg)
5.lipid profile
6.renal function: eGFR (ml/min/1.73m2)
7.liver function: AST, ALT, GGT
8.FIB-4 index
3: Association the change of HbA1c and several factors as follow between two groups.
1.GA
2.FPG (mg/dL)
3.systolic blood pressure (mmHg)
4.diastolic blood pressure (mmHg)
5.lipid profile
6.renal function: eGFR (ml/min/1.73m2)
7.liver function: AST, ALT, GGT
8.FIB-4 index
9.body weight (kg), BMI (kg/mm2)
10.detail of medication and number of take medicine
4: Association the change of body weight and several factors as follow between two groups.
1.GA
2.FPG (mg/dL)
3.systolic blood pressure (mmHg)
4.diastolic blood pressure (mmHg)
5.lipid profile
6.renal function: eGFR (ml/min/1.73m2)
7.liver function: AST, ALT, GGT
8.FIB-4 index
9.HbA1c (%)
10.detail of medication and number of take medicine

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control Placebo
Stratification NO
Dynamic allocation NO
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Behavior,custom
Interventions/Control_1 Provide normal nutritional guidance plus instruct to double their meal intake time for dinner.
Interventions/Control_2 Provide normal nutritional guidance.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria The selection criteria for the subjects are as follow.
1. Patients who have been diagnosed as type 2 diabetes.
2. Over 20 years old.
Key exclusion criteria The exclusion criteria for the subjects are as follow.
1. Subjects with acute and/or chronic inflammation
2. Subjects with fresh cardiovascular and/or cerebrovascular diseases
3. Subjects with liver cirrhosis.
4. Subjects with severe respiratory disease or severe heart failure
5. Subjects with alcoholicsm or medicinal intoxication
6. Subjects with psychosis
7. Subjects who doctors judge as unfitness
Target sample size 80

Research contact person
Name of lead principal investigator
1st name Takeshi
Middle name
Last name Matsumura
Organization Nishinihon Hospital
Division name Metabolic Medicine
Zip code 861-8034
Address 3-20-1 Hattanda, Higashi-ku, Kumamoto
TEL 096-380-1111
Email takeshim@gpo.kumamoto-u.ac.jp

Public contact
Name of contact person
1st name Hongo
Middle name
Last name Emi
Organization Nishinihon Hospital
Division name Department of Nutrition
Zip code 861-8034
Address 3-20-1 Hattanda, Higashi-ku, Kumamoto
TEL 0963801111
Homepage URL
Email hcaelb_a@yahoo.co.jp

Sponsor
Institute Department of Metabolic Medicine, Nishinihon Hospital
Institute
Department

Funding Source
Organization Self funding

Department of Metabolic Medicine, Nishinihon Hospital

Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Nishinihon Hospital Ethics Review Committee
Address 3-20-1 Hattanda, Higashi-ku, Kumamoto
Tel 0963801111
Email takeshim@gpo.kumamoto-u.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 西日本病院(熊本)

Other administrative information
Date of disclosure of the study information
2022 Year 02 Month 13 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2022 Year 02 Month 13 Day
Date of IRB
2022 Year 01 Month 19 Day
Anticipated trial start date
2022 Year 02 Month 13 Day
Last follow-up date
2024 Year 01 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2022 Year 02 Month 13 Day
Last modified on
2022 Year 02 Month 13 Day


Link to view the page
URL(English) https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053504